Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 8/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
| ▸ | F11 | P03951 | 3/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 4/20 | 0.37 |
| ▸ | CDK7 | P50613 | 4/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL938433 | 1.00 | ROCK2 (0.43) | ROCK2KDM4EALDH1A1BRD4F11 | |
| SCHEMBL4146643 | 0.83 | ROCK2 (0.43) | ROCK2KDM4EALDH1A1BRD4F11 | |
| SCHEMBL4158845 | 0.80 | ROCK2 (0.41) | ROCK2KDM4EALDH1A1BRD4F11 | |
| SCHEMBL3434356 | 0.76 | ROCK2 (0.40) | ROCK2F11CDK2CDK7ROCK1 | |
| SCHEMBL1196662 | 0.75 | ROCK2 (0.48) | ROCK2KDM4EALDH1A1F11KLKB1 | |
| SCHEMBL1196664 | 0.75 | ROCK2 (0.48) | ROCK2KDM4EALDH1A1F11KLKB1 | |
| SCHEMBL13554564 | 0.75 | ROCK2 (0.48) | ROCK2KDM4EALDH1A1BRD4F11 | |
| SCHEMBL9724160 | 0.72 | KDM4E (0.64) | KDM4EALDH1A1BRD4TLR8TLR7 | |
| SCHEMBL479101 | 0.68 | F11 (0.51) | ROCK2F11KLKB1ROCK1 | |
| SCHEMBL479102 | 0.68 | F11 (0.51) | ROCK2F11KLKB1ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324199-B2 | Pyridazine derivatives as factor xia inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-04 | — | — | US | disclosed |
| US-20110021492-A1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021492-A1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | F11, F12, TFPI2 | ROCK2 596/4885KDM4E 1441/4885ALDH1A1 2830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.